Metraipolis › archive › dc_861471348bc9

Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States — Europe PMC PMID:42932296

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42932296
DOI
10.1371/journal.pone.0353373
License (as archived)
solo-consultazione
Archived
2026-10-31T20:01:46.519Z
SHA-256 of the archived text
84b4312da0f557624f79231ef8a28e362813194c06b0984bb6623ddc9f32fc05
Stable URL of this page
https://metraipolis.com/documento/dc_861471348bc9

How to cite

Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States — Europe PMC PMID:42932296 — Europe PMC (en), https://europepmc.org/article/MED/42932296 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_861471348bc9 (Metraipolis archive dc_861471348bc9, sha256 84b4312da0f557624f79231ef8a28e362813194c06b0984bb6623ddc9f32fc05)
BibTeX
@misc{dc861471348bc9,
  title = {Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States — Europe PMC PMID:42932296},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42932296},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_861471348bc9; sha256 84b4312da0f557624f79231ef8a28e362813194c06b0984bb6623ddc9f32fc05},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42932296. Agents can read the archived copy with the MCP tool read_document.